US Tech Transfer Blooms For BMS Under Allied Minds JV
Bristol-Myers Squibb Co. entered a joint venture two years ago with US IP commercialization firm Allied Minds to identify innovation from US universities and research institutions. The project is beginning to bear fruit, and the JV has now secured $100m to fund up to 10 promising drug development opportunities. Allied Minds CEO Chris Silva talks to Scrip's Sukaina Virji about what happens next.
Register for our free email digests: